Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
RBC cuts Regeneron stock price target to $1,045, keeps Outperform
RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Jefferies Sticks to Their Buy Rating for Regeneron (REGN)
In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Regeneron upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...